Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Lysosomal Acid Lipase Deficiency: full-pipeline trial registry
1 of 3 indexed Lysosomal Acid Lipase Deficiency trials are currently recruiting.
Corpus placement: #5,209 of 28,707 conditions by registered trial count.
3 US clinical trials · 1 currently recruiting · #5,209 of 28,707 conditions by registered trial count
Lysosomal Acid Lipase Deficiency: 3 US clinical trials tracked, 1 recruiting.
Lysosomal Acid Lipase Deficiency is the subject of 3 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is Alexion Pharmaceuticals, running 3 of these trials.
Enrollment posture brief
Registry condition lysosomal-acid-lipase-deficiency
OPEN 1 | RECR 33% | LATE 1 | EARLY 1 | RANK #5209 | SPON 3
Volume-matched condition peers
Nearest open-share peer: Adherence, Treatment (33% recruiting · 6 trials)
Lysosomal Acid Lipase Deficiency lists 1 open slots (33% of 3 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Lysosomal Acid Lipase Deficiency on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Lysosomal Acid Lipase Deficiency is recruiting below its size-band peers.
1 of 3 indexed trials (33.3%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
3 total, page 1 of 1
Lysosomal Acid Lipase (LAL) Deficiency Registry
Alexion Pharmaceuticals
NCT01633489
Acid Lipase Replacement Investigating Safety and Efficacy (ARISE) in Participants With Lysosomal Acid Lipase Deficiency
Alexion Pharmaceuticals
NCT01757184
Safety and Efficacy Study of Sebelipase Alfa in Participants With Lysosomal Acid Lipase Deficiency
Alexion Pharmaceuticals
NCT02112994
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 1 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Lysosomal Acid Lipase Deficiency records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Lysosomal Acid Lipase Deficiency trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Lysosomal Acid Lipase Deficiency page
3 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 1 Lysosomal Acid Lipase Deficiency trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Alexion Pharmaceuticals sponsors the most Lysosomal Acid Lipase Deficiency trials on record, review their full trial history before evaluating a specific study. See Alexion Pharmaceuticals's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Lysosomal Acid Lipase Deficiency condition card totals 3 registered trials; most-linked intervention Sebelipase Alfa; top US site state Illinois. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.